InnoSIGN is an mRNA-based pathway activity profiling technique that aims to transform precision medicine by providing greater insight into disease causes. The company proposes to use its enormous library of pathway activity profiles to enhance diagnostics and drug discovery, giving researchers with qPCR tests for decentralized use through a service testing facility in the Netherlands.
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug capable of delivering a disease-modifying approach and preserving cognition in patients.
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Clinical Maestro™ by Strategikon Pharma is the only commercially available software platform for the end- to- end management of “clinical business operations”, which is the pharmaceutical industry vertical for planning, outsourcing and budgeting clinical trials. Biopharmaceutical companies outsource 90% of their clinical development pipeline spending billions of dollars engaging in highly complex outsourced relationships with thousands of global service providers, each using their own processes, systems and reporting structures. These sophisticated relationships require complex outsourcing strategies, demanding clinical financial planning, extensive sourcing due diligence and rigorous performance management. Currently the industry manages these activities in Excel, using labor intensive, inefficient processes, costing billions of dollars in infrastructure costs, regulatory non-compliance fines and delays to market. Clinical Maestro takes a radically different approach to the management of clinical portfolio through a transformative redesign of Excel-driven processes into end-to-end integrated workflows, breaking the communication and data integration siloes between pharma companies and their outsourcing partners. Clinical Maestro™ cases studies with leading pharmaceutical companies and CROs demonstrate savings of >80% vs. manual processes, >95% prediction accuracy for clinical study budgets and high user satisfaction and engagement.
Visicell Medical is a company that creates safe and biodegradable stem cell tracking tools in order to bring stem cell-based therapy to patients suffering from incurable diseases. Their tracking tools enable doctors to easily track stem cells planted in patients by allowing real-time tracking of injected stem cells in subjects with compatibility in both clinical and pre-clinical settings.
Avisi Technologies develops VisiPlate, a next-generation, nanotechnology-enabled aqueous shunt intended to treat glaucoma.
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug capable of delivering a disease-modifying approach and preserving cognition in patients.
Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company’s TrapTx Analyzer System uniquely integrates both phenotypic and genomic data at massive scale (up to tens of thousands of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology.
Saccharo is a biotech start-up in the immuno-oncology space that develops therapeutic products for the treatment of cancer and other novel diseases. Saccharo discovered a polysaccharide that surrounds human cancer cells. The Sacchario approach has a mechanism of action that allows drugs to have multiple killing effects, a predicted safety profile, a broad therapeutic window, and applications to many cancers. Saccharo was established in 2017 by Sherry Martin-Moe and Gregory Moe in Oakland, California.
Clinical Maestro™ by Strategikon Pharma is the only commercially available software platform for the end- to- end management of “clinical business operations”, which is the pharmaceutical industry vertical for planning, outsourcing and budgeting clinical trials. Biopharmaceutical companies outsource 90% of their clinical development pipeline spending billions of dollars engaging in highly complex outsourced relationships with thousands of global service providers, each using their own processes, systems and reporting structures. These sophisticated relationships require complex outsourcing strategies, demanding clinical financial planning, extensive sourcing due diligence and rigorous performance management. Currently the industry manages these activities in Excel, using labor intensive, inefficient processes, costing billions of dollars in infrastructure costs, regulatory non-compliance fines and delays to market. Clinical Maestro takes a radically different approach to the management of clinical portfolio through a transformative redesign of Excel-driven processes into end-to-end integrated workflows, breaking the communication and data integration siloes between pharma companies and their outsourcing partners. Clinical Maestro™ cases studies with leading pharmaceutical companies and CROs demonstrate savings of >80% vs. manual processes, >95% prediction accuracy for clinical study budgets and high user satisfaction and engagement.
Anubis Bio has USPTO patented Microbiome-Cleanser (TM) natural food platform that quickly resolves GI-distress-diarrhea in animals starting with dogs (www.doggystat.com). Two major B2B distribution partnerships signed in 2021.
Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness.
S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications. It enables automated processing of raw tissues into single cells or nuclei for genomics and cell biology studies. The company's vision is to provide products that process raw tissues into samples ready for genomic analyses. S2 Genomics was founded in 2016 and is headquartered in Livermore, CA.
BioTrace Medical is dedicated to reinventing temporary pacing to improve patient outcomes and reduce hospital costs. BioTrace Medical is a stealth-stage company focused on the production of medical devices. The company was founded by Aravind Swaminathan and Ellis Garai in 2013 and is based in San Mateo, California.
Identical is a developer of personalized dental implants used to make tooth replacement more accessible and affordable for everyone. Its implants are drill-free and non-invasive and use the latest 3D technology that enables dentists to deliver personalized dental implants in a faster and safer way. It was founded in 2018 and is headquartered in Walnut Creek, California.
Stimwave Technologies, Inc., a medical device company, engages in the development, manufacture, commercialization, and marketing of wireless microsize injectable medical devices for neurology markets. The company was formerly known as Neural Micro Incorporated. Stimwave Technologies, Inc. was incorporated in 2010 and is based in Scottsdale, Arizona.
EuMentis Therapeutics Inc., a biopharmaceutical company, develops novel therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. The company offers a nitroaminoadamantane N-methyl-D-aspartate (NMDA) receptor antagonist, EM-036, for the treatment of Alzheimer's disease and autism-spectrum disorders. It also provides pre-clinical study, development, and testing services. The company was incorporated in 2019 and is based in Newton, Massachusetts.
Inhalon Biopharma is into developing monoclonal antibodies (mAb) using technology that enables trapping of pathogens in mucus secretions for treating diseases of the respiratory tract.
Sandstone Diagnostics offers a centrifuge system that provides plasma and serum collection at-home and the point-of-care. It specializes in the fields of clinical diagnostics, home healthcare, and fertility. It was founded in 2012 and headquartered in Pleasanton, California.
S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications. It enables automated processing of raw tissues into single cells or nuclei for genomics and cell biology studies. The company's vision is to provide products that process raw tissues into samples ready for genomic analyses. S2 Genomics was founded in 2016 and is headquartered in Livermore, CA.
VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral and the Tricuspid valves; offering a viable alternative to open heart surgery.
Embolx is a venture-backed start-up in Silicon Valley that is developing and commercializing unique catheter-based systems that enable a breakthrough in minimally invasive localized cancer therapy. Embolx devices use pressure regulation to eliminate non-target delivery and increase drug distribution in the tumor using an advanced method known as Low Pressure Embolization (LPE).
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia and lymphoma, have shown transformative results for patients unresponsive to standard therapy. However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients. Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w
Chameleon is changing the way they treat genetic diseases using gene therapy to deliver corrective genes using multiple systemic dose administrations. Research indicates that 20-30% of all infant fatalities are due to genetic disorders, and for those who survive, treatment options are often limited. Recent breakthroughs in gene therapy are saving lives, but there's still a long way to go. At Chameleon, their goal is to ensure every child can be treated with lower doses and accurate target specificity over time as their condition requires. They are committed to every child and family who suffers from a genetic disorder. Their mission is to make sure every Belle, Abby and Marian live to their 10th birthdays, learn to drive, go to prom and someday have healthy children of their very own.
TeVido will change the way reconstructive surgery is approached, starting by improving options for those who have lost skin color from scarring or disease. We will expand capability to others who suffer disfigurement and long to improve their self-esteem. In addition to reconstruction, TeVido technology will be applicable across a wide variety of needs for wound healing and cosmetic surgery.
First Light Biosciences develops breakthrough automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare-Associated Infections (HAI). The products address the need for cost-effective and accurate diagnostics to meet the explosive growth in testing. New testing is being driven by clinical studies showing that testing for infectious agents can help to dramatically lower the rate of hospital infections. Based on its proprietary MultiPath detection technology, First Light’s products combine the performance of the most advanced commercial laboratory tests with unprecedented affordability and ease-of-use.
TransformativeMed their platform of EHR solutions, enables doctors and nurses to access patient data across clinical specialties and departments.
Purissima has developed a unique platform to produce active pharmaceutical ingredient (API) grade molecules through the fermentation of heterotrophic microalgae.
S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications. It enables automated processing of raw tissues into single cells or nuclei for genomics and cell biology studies. The company's vision is to provide products that process raw tissues into samples ready for genomic analyses. S2 Genomics was founded in 2016 and is headquartered in Livermore, CA.
Virion Therapeutics is a science-driven company developing innovative immune-based treatments for virally associated cancers and chronic viral infections. Their vaccines, ChiVax and ChiVax-gD, represent novel and highly effective platforms to induce potently and sustained T cell-mediated immune responses against transformed or infected cells, thereby targets common diseases with unmet medical needs. Each component comprising chimeric vaccine candidates has completed pre-clinical testing that allows for their translation into clinical trials for several different indications. Guided by their scientific and management expertise, these platforms may help cure such devastating diseases as HPV-induced cancers and chronic Hepatitis B infections. Virion Therapeutics was founded in 2018 and is headquartered in Newark, Delaware.
InvVax is a vaccine development company with a proprietary platform building breakthrough vaccines. Our initial product is a universal influenza vaccine.
TheraDep provides drug delivery coatings for microneedles and labware coatings. They work with medical device and pharmaceutical companies to develop innovative drug delivery products.
Seal Rock Therapeutics is a developer of small-molecule inhibitors of ASK1 (Apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis. Additional opportunities with ASK1 inhibitors include cardiac, immunological, and neurodegenerative indications.
Ark.one Health develops a predictive analytics platform for health care systems and plans. The company provides financial performance improvement analytics to health systems as a service.
Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation.
Nanotech Biomachines develops a sensor technology for therapeutic discovery and development applications.
Seal Rock Therapeutics is a developer of small-molecule inhibitors of ASK1 (Apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis. Additional opportunities with ASK1 inhibitors include cardiac, immunological, and neurodegenerative indications.
Embolx is a venture-backed start-up in Silicon Valley that is developing and commercializing unique catheter-based systems that enable a breakthrough in minimally invasive localized cancer therapy. Embolx devices use pressure regulation to eliminate non-target delivery and increase drug distribution in the tumor using an advanced method known as Low Pressure Embolization (LPE).
InvVax is a vaccine development company with a proprietary platform building breakthrough vaccines. Our initial product is a universal influenza vaccine.
Embolx is a venture-backed start-up in Silicon Valley that is developing and commercializing unique catheter-based systems that enable a breakthrough in minimally invasive localized cancer therapy. Embolx devices use pressure regulation to eliminate non-target delivery and increase drug distribution in the tumor using an advanced method known as Low Pressure Embolization (LPE).
Vet24seven, Inc. introduces Ask.Vet, the online community where veterinarians engage and interact with animal owners to provide trusted, expert advice, information, & resources that help them with the care, health, and well-being of their animals. Ask.Vet was designed as the ‘go-to’ destination for the two hundred million households with animals around the world. Questions are routed to a licensed veterinarian who is trained to educate, direct, and refer the client to a veterinarian, veterinary hospital, or other service providers nearby for diagnosis, treatment, and care. Veterinarians, clinics, and product/service providers will pay a referral free to Ask.Vet for qualified leads.
Vet24seven, Inc. introduces Ask.Vet, the online community where veterinarians engage and interact with animal owners to provide trusted, expert advice, information, & resources that help them with the care, health, and well-being of their animals. Ask.Vet was designed as the ‘go-to’ destination for the two hundred million households with animals around the world. Questions are routed to a licensed veterinarian who is trained to educate, direct, and refer the client to a veterinarian, veterinary hospital, or other service providers nearby for diagnosis, treatment, and care. Veterinarians, clinics, and product/service providers will pay a referral free to Ask.Vet for qualified leads.
Thrive Bioscience is commercializing a family of instruments and software that provide imaging, analytics, and automation to significantly improve cell culture and the analysis of live cells. Thrive’s instruments empower biologists to deliver consistent, reproducible results by leveraging microscopy, robotics, fluidics, and other fields, to capture images and data and provide analysis, reports, guidance, documentation, and a database on the cells and on cell culture processes.
InvVax is a vaccine development company with a proprietary platform building breakthrough vaccines. Our initial product is a universal influenza vaccine.
Retrotope creates a new category of drug platform to preserve and restore mitochondrial health in degenerative diseases. It is a privately held company focused on the development of ways of controlling metabolic processes associated with oxidative stress conditions. Retrotope uses isotope effect to slow down damaging pathways. The company has several discovery and development programs that involve major classes of biopolymers, with the major focus on neurological diseases such as Friedreich's ataxia. It was founded in 2006 and is located in Los Altos Hills, California.
Vet24seven, Inc. introduces Ask.Vet, the online community where veterinarians engage and interact with animal owners to provide trusted, expert advice, information, & resources that help them with the care, health, and well-being of their animals. Ask.Vet was designed as the ‘go-to’ destination for the two hundred million households with animals around the world. Questions are routed to a licensed veterinarian who is trained to educate, direct, and refer the client to a veterinarian, veterinary hospital, or other service providers nearby for diagnosis, treatment, and care. Veterinarians, clinics, and product/service providers will pay a referral free to Ask.Vet for qualified leads.
Zephyrus Biosciences provides research tools to enable protein analysis at the single-cell level. Addressing the burgeoning single-cell analysis market, our first product, the scWestern system, enables western blotting on individual cells for the first time. Researchers will utilize Zephyrus’s products to gain new insights into the biology of cancer, stem cells, neurology, and human disease and development. It was founded in 2013 and headquartered in Berkeley, California.
Nanotech Biomachines develops a sensor technology for therapeutic discovery and development applications.
Sandstone Diagnostics is a Bay Area biotech company developing instruments and consumables for point-of-care medical testing. Sandstone’s lead product, Trak, is a consumer semen analysis platform that provides a simple and accurate way to monitor sperm quality from the comfort of home. Trak is a tool for men to take charge of their fertility, boost their sperm quality, and improve their chances of conception. Sandstone was co-founded in 2012 by Ph.D. scientists developing medical technologies for national defense applications at Sandia National Laboratories.
Gemmus Pharma is a drug development company founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.
Physcient develops modern technology for hand-held surgical instruments that enable speedy recovery without changing surgical procedures. It was founded in 2007 by three scientists/executives with over 75 years of experience developing new technologies for the life and health sciences.
Carmenta Bioscience is a privately held medical technology company dedicated to improving maternal and fetal health. Spun-out of Stanford University School of Medicine in 2012, Carmenta Bioscience is currently developing a highly accurate, serum-based diagnostic test for preeclampsia.
NuMedii is a biotechnology company that discovers and de-risks effective new drugs by translating life sciences big data into therapies. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii. It utilizes hundreds of millions of raw human, biological, pharmacological, and clinical data points. The company was founded in 2008 and headquartered in San Mateo, California.
Nanostim is an early-stage medical device company working to prevent more than 100,000 annual complications related to pacemakers. Nanostim has assembled a world-class team of experienced medical device engineers to help bring this exciting technology to the marketplace.
NVISION MEDICAL Corporation operates in the healthcare sector. The company was incorporated in 2009 and is based in Saratoga, California. nVision is a privately-held medical device company dedicated to filling the void in women’s health innovation. Since its founding in 2011, the company has relentlessly focused on developing devices to enable clinicians to assess the health of previously inaccessible parts of the female reproductive tract.
Gemmus Pharma is a drug development company founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.
Niveus Medical develops and offers technologies to keep key muscle groups strong during periods of sedation and bed rest so as to accelerate patient recovery in the ICU. It owns the brand IntelliSTIM. The company's muscle-stimulation systems provide comfortable and effective stimulation to the quadriceps and increase local blood circulation, enabling patients to begin treatment more quickly and result in a higher likelihood of successful treatment. Niveus Medical was founded in 2008 and is based in Palo Alto, California.
MoMelan Technologies, Inc. operates as a developer of a device to treat skin disorders by expanding the surface area of skin grafts. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.
OncoHealth designs screening devices that detects and diagnoses cancer. Its devices focus on the development of protein bio-markers for screening and diagnostics of cervical cancer and other HPV-associated cancers, enabling medical professionals to monitor, diagnose, and treat cancer.
OncoHealth designs screening devices that detects and diagnoses cancer. Its devices focus on the development of protein bio-markers for screening and diagnostics of cervical cancer and other HPV-associated cancers, enabling medical professionals to monitor, diagnose, and treat cancer.
Allylix, Inc., an early stage biotechnology company, develops terpene products and their derivatives for the flavor and fragrance, food ingredient, pharmaceutical, agricultural, and biofuel markets. Its products comprise nootkatone, which is a grapefruit flavor that is used in fruit juices and citrus flavored sodas. The company also develops sesquiterpenes that are part of aroma chemical segment of the flavor and fragrance market; and production platforms for pharmaceutical, nutraceutical, and agricultural markets. Allylix, Inc. was founded in 2002 and is based in San Diego, California with research and development laboratories in Lexington, Kentucky.
Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.
Vaxart is a clinical-stage company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform and direct-acting antivirals to treat infections that have limited therapeutic options. Vaxart’s oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Vaxart’s oral vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines, and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). Through the merger, Vaxart also acquired antiviral drug candidates, including teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV types 6 and 11.
Velomedix, Inc. is a therapeutic hypothermia company in the United States. Its therapeutic hypothermia technology offers a novel solution for the protection of the body's organs during ischemic or inflammatory insults. Velomedix, Inc. is based in Menlo Park, California.
Verdezyne was a privately-held company that employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways, and microorganisms. The company creates and harnesses this unique biological diversity to optimize commercial fermentation processes for the production of petrochemical replacements.
Breathe Technologies, Inc was founded in 2005 with the objective of empowering healthcare providers and patients with new, reliable and accessible respiratory therapies that optimize breathing and mobility. They are in the process of developing truly ultra-light, compact, patient-friendly ventilator systems that can transform respiratory care in the hospital and home markets.
Satoris develops tests for neurological diseases such as Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy. They're committed to developing and commercializing neurodiagnostic tests that yield the earliest, most accurate, and most clinically relevant diagnoses, so that healthcare costs can be reduced while patient care becomes even more effective.
Allylix, Inc., an early stage biotechnology company, develops terpene products and their derivatives for the flavor and fragrance, food ingredient, pharmaceutical, agricultural, and biofuel markets. Its products comprise nootkatone, which is a grapefruit flavor that is used in fruit juices and citrus flavored sodas. The company also develops sesquiterpenes that are part of aroma chemical segment of the flavor and fragrance market; and production platforms for pharmaceutical, nutraceutical, and agricultural markets. Allylix, Inc. was founded in 2002 and is based in San Diego, California with research and development laboratories in Lexington, Kentucky.
Vaxart is a clinical-stage company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform and direct-acting antivirals to treat infections that have limited therapeutic options. Vaxart’s oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Vaxart’s oral vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines, and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). Through the merger, Vaxart also acquired antiviral drug candidates, including teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV types 6 and 11.
Fluxion Biosciences was formed in 2005 to address critical needs for cellular analysis tools in the pharmaceutical, biotech and research industries. The company has developed a proprietary microfluidic platform which enables precise cellular manipulation, rapid low-volume compound addition, environmental control and software-based data acquisition.
Verdezyne was a privately-held company that employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways, and microorganisms. The company creates and harnesses this unique biological diversity to optimize commercial fermentation processes for the production of petrochemical replacements.
VasoNova, Inc. manufactures and markets medical devices. It develops a self-guided PICC catheter. The company is based in Sunnyvale, California.
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.
Verdezyne was a privately-held company that employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways, and microorganisms. The company creates and harnesses this unique biological diversity to optimize commercial fermentation processes for the production of petrochemical replacements.
Pegasus Biologics, Inc. engages in manufacturing, developing, and marketing bioimplants for soft tissue repair and wound care for diabetic ulcers. Its products include OrthADAPT Bioimplant, which is an organized tissue scaffold that used for the repair and reinforcement of soft tissues, such as tendons and ligaments; and Unite Biomatrix, which is an enzyme resistant collagen scaffold that allows for suture retention and intrinsic strength. The company serves orthopedics, sports medicine, neurosurgical, and spine applications. Pegasus Biologics, Inc. was founded in 2003 and is based in Irvine, California. As of July 17, 2009, Pegasus Biologics, Inc. operates as a subsidiary of Synovis Life Technologies Inc.